drugset / Trial / NCT03652077
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
Timeline
- Start
- 2018-09-24
- Primary completion
- 2021-08-18
- Completion
- 2021-08-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Verzistobart | Monoclonal antibody | — | — |
Indications
cervical cancer
cutaneous neuroendocrine carcinoma
esophageal cancer
gastric cancer
gastroesophageal cancer
head and neck squamous cell carcinoma
hepatocellular carcinoma
mesothelioma
non-small cell lung carcinoma
ovarian cancer
renal cell carcinoma
small cell lung carcinoma
triple-negative breast carcinoma
urothelial carcinoma
uveal melanoma